FATE vs FENC

Fate Therapeutics, Inc. vs Fennec Pharmaceuticals Inc. — Valuation Comparison 2026

FATE

Biotechnology
Fate Therapeutics, Inc.
Quality
5.5
out of 10
Value Trap
24
SAFE
Price
$2.63
Last close
Models
9/13
Active
VS

FENC

Biotechnology
Fennec Pharmaceuticals Inc.
Quality
6.3
out of 10
Value Trap
6
SAFE
Price
$9.89
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType FATE Fair ValueFATE Upside FENC Fair ValueFENC Upside
Bayesian DCF Intrinsic $0.62 -76.3% $1.70 -82.8%
First Chicago Scenario $0.48 -68.8% $2.52 -74.5%
ML-RIV Intrinsic $0.18 -88.1% $0.09 -98.6%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for FATE vs FENC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

FATE vs FENC — Which Stock Is More Undervalued?

FENC scores higher with a 6.3/10 quality rating vs FATE's 5.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Fate Therapeutics, Inc. (FATE) and Fennec Pharmaceuticals Inc. (FENC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

FATE currently trades at $2.63 with a QOC of 5.5/10, while FENC trades at $9.89 with a QOC of 6.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).